A phase 2 study of DISC-3405 in polycythemia vera (PV)
Latest Information Update: 15 Nov 2024
Price :
$35 *
At a glance
- Drugs 9MW 3011 (Primary)
- Indications Polycythaemia vera
- Focus Therapeutic Use
- 15 Nov 2024 New trial record
- 08 Nov 2024 According to Disc Medicine media release, the company has obtained a $200 million non-dilutive term loan facility from Hercules Capital, which will support this Phase 2 study of DISC-3405 in polycythemia vera (PV) along with other studies.